about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

#Eu­ro­Bio23: The down­turn, tak­ing risks and the ‘biotech mafia’

Last year
People
Financing

Tem­pest eyes piv­otal tri­al for liv­er can­cer drug af­ter un­veil­ing ear­ly PFS, OS da­ta

Last year
R&D

Up­dat­ed: GSK taps Chi­nese part­ner to ramp up Shin­grix sales in $3.05B deal, with op­tion to ex­pand to RSV

Last year
Deals
China

Pi­o­neers of mR­NA win No­bel — plus our in­ter­view; Eli Lil­ly’s M&A, lead­er­ship shuf­fle; UniQure lay­offs as gene ...

Last year
Weekly

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics sells to Ky­owa Kirin for $387M cash as lead pro­gram awaits 2024 FDA ver­dict

Last year
Deals
Cell/Gene Tx

Sanofi slides J&J’s E. coli vac­cine in­to late-stage port­fo­lio, bet­ting $175M cash on de­vel­op­ment, com­mer­cial­iza­tion ...

Last year
Deals

Ex­clu­sive: Di­men­sion leads $40M round for lab au­toma­tion com­pa­ny Au­toma­ta Tech­nolo­gies

Last year
Financing

Katal­in Karikó, Drew Weiss­man win No­bel Prize for mR­NA dis­cov­er­ies

Last year
People

Tak­ing pulse on pri­vate biotech fund­ing; Q&A with Iso­mor­phic Labs CEO; Re­search in­sti­tu­tions re­thinks deal­mak­ing; and ...

Last year
Weekly

With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

Last year
Financing

Ab­cam founder urges in­vestors to vote against Dana­her's $5.7B buy­out, seeks to re­turn as CEO

Last year
People

Pox­el takes write­down on NASH drug as it con­tin­ues lay­offs, search for cash

Last year
People

The 2023 End­points 11; Re­gen­eron’s gene edit­ing am­bi­tions; GSK’s re­search re­vamp; Rip­ple ef­fect of Dana-Far­ber, ...

Last year
Weekly

Six years af­ter with­draw­ing IPO, Abpro takes SPAC route to Nas­daq — with plans to take HER2 bis­pe­cif­ic to clin­ic

Last year
Deals

Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

Last year
Deals

Mod­er­na's R&D game plan; 2sev­en­ty lay­offs amid CAR-T slow­down; Covid vac­cine boost­ers get thumbs up; and more

Last year
Weekly

Late­com­er Am­gen takes 'plat­form ap­proach' in obe­si­ty as PhII da­ta loom

Last year
R&D
Pharma

Neu­ro­crine plots 2024 fil­ing for rare dis­ease drug af­ter 'solid' PhI­II win

Last year
R&D

Up­dat­ed: 2sev­en­ty lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO

Last year
People
Cell/Gene Tx

Di­anthus marks Nas­daq de­but with PhI hit; Ar­bu­tus shuts oral RNA and coro­n­avirus pro­grams

Last year
News Briefing

As­traZeneca's Tagris­so/chemo com­bo staves off lung can­cer for al­most nine months. But will side ef­fects lim­it its ...

Last year
R&D

Biotech megarounds ga­lore; New lead­ers at No­var­tis, Bio­gen; State of play for GLP-1 in NASH; In­side Il­lu­mi­na’s CEO ...

Last year
Weekly

Seagen teams up with pro­tein degra­da­tion spe­cial­ist to make a new kind of an­ti­body con­ju­gate, pay­ing $60M up­front

Last year
Deals

J&J shut­ters PhI­II tri­al for pul­monary hy­per­ten­sion drug, block­ing its ex­pand­ed use as patent ex­piry looms

Last year
R&D
Pharma
First page Previous page 6789101112 Next page Last page
A service from the Financial Times